Apollomics Inc.’s APLM stock soared on Tuesday after the company released promising preliminary clinical data from its Phase 2 SPARTA trial. The data showed a significant objective response rate (ORR) and favorable survival outcomes for patients with non-CNS MET fusion solid tumors treated with vebreltinib, a potential new treatment option for these cancers.